Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Unless a significant macroeconomic shock occurs, Bitcoin's mid-term prospects remain constructive, with the potential to ...

HYPE has declined 3.3% in 24 hours to $45.13 despite Hyperliquid platform recording historic $18.99 billion daily perpetuals ...

Stay updated with real-time stock market news, Sensex & Nifty movements, top gainers and losers, expert analysis, IPO updates ...

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

The first half of 2025 was a roller-coaster ride for investors with the broader market surging to new highs at the beginning ...